Literature DB >> 25271156

Identification of serine 348 on the apelin receptor as a novel regulatory phosphorylation site in apelin-13-induced G protein-independent biased signaling.

Xiaoyu Chen1, Bo Bai2, Yanjun Tian3, Hui Du4, Jing Chen5.   

Abstract

Phosphorylation plays vital roles in the regulation of G protein-coupled receptor (GPCR) functions. The apelin and apelin receptor (APJ) system is involved in the regulation of cardiovascular function and central control of body homeostasis. Here, using tandem mass spectrometry, we first identified phosphorylated serine residues in the C terminus of APJ. To determine the role of phosphorylation sites in APJ-mediated G protein-dependent and -independent signaling and function, we induced a mutation in the C-terminal serine residues and examined their effects on the interaction between APJ with G protein or GRK/β-arrestin and their downstream signaling. Mutation of serine 348 led to an elimination of both GRK and β-arrestin recruitment to APJ induced by apelin-13. Moreover, APJ internalization and G protein-independent ERK signaling were also abolished by point mutation at serine 348. In contrast, this mutant at serine residues had no demonstrable impact on apelin-13-induced G protein activation and its intracellular signaling. These findings suggest that mutation of serine 348 resulted in inactive GRK/β-arrestin. However, there was no change in the active G protein thus, APJ conformation was biased. These results provide important information on the molecular interplay and impact of the APJ function, which may be extrapolated to design novel drugs for cardiac hypertrophy based on this biased signal pathway.
© 2014 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  7-Helix Receptor; Apelin Receptor (APJ); Biased Signal Pathway; Bioluminescence Resonance Energy Transfer (BRET); G Protein-coupled Receptor (GPCR); Protein Phosphorylation; Signal Transduction

Mesh:

Substances:

Year:  2014        PMID: 25271156      PMCID: PMC4223320          DOI: 10.1074/jbc.M114.574020

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  56 in total

Review 1.  Beta-arrestins and cell signaling.

Authors:  Scott M DeWire; Seungkirl Ahn; Robert J Lefkowitz; Sudha K Shenoy
Journal:  Annu Rev Physiol       Date:  2007       Impact factor: 19.318

2.  Apelin protects myocardial injury induced by isoproterenol in rats.

Authors:  Yue-Xia Jia; Chun-Shui Pan; Jing Zhang; Bin Geng; Jing Zhao; Helen Gerns; Jun Yang; Jaw-Kang Chang; Chao-Shu Tang; Yong-Fen Qi
Journal:  Regul Pept       Date:  2005-11-08

3.  beta-arrestin-dependent, G protein-independent ERK1/2 activation by the beta2 adrenergic receptor.

Authors:  Sudha K Shenoy; Matthew T Drake; Christopher D Nelson; Daniel A Houtz; Kunhong Xiao; Srinivasan Madabushi; Eric Reiter; Richard T Premont; Olivier Lichtarge; Robert J Lefkowitz
Journal:  J Biol Chem       Date:  2005-11-09       Impact factor: 5.157

4.  Phosphorylation of the endogenous thyrotropin-releasing hormone receptor in pituitary GH3 cells and pituitary tissue revealed by phosphosite-specific antibodies.

Authors:  Brian W Jones; Gyun Jee Song; Emileigh K Greuber; Patricia M Hinkle
Journal:  J Biol Chem       Date:  2007-02-28       Impact factor: 5.157

5.  Characterization of G-protein coupled receptor kinase interaction with the neurokinin-1 receptor using bioluminescence resonance energy transfer.

Authors:  Rasmus Jorgensen; Nicholas D Holliday; Jakob L Hansen; Milka Vrecl; Anders Heding; Thue W Schwartz; Christian E Elling
Journal:  Mol Pharmacol       Date:  2007-11-06       Impact factor: 4.436

6.  Apelin-13 induces ERK1/2 but not p38 MAPK activation through coupling of the human apelin receptor to the Gi2 pathway.

Authors:  Bo Bai; Jiyou Tang; Haiqing Liu; Jing Chen; Yalin Li; Wengang Song
Journal:  Acta Biochim Biophys Sin (Shanghai)       Date:  2008-04       Impact factor: 3.848

7.  G protein-coupled receptor kinase-mediated phosphorylation regulates post-endocytic trafficking of the D2 dopamine receptor.

Authors:  Yoon Namkung; Concetta Dipace; Jonathan A Javitch; David R Sibley
Journal:  J Biol Chem       Date:  2009-03-30       Impact factor: 5.157

Review 8.  Arrestins: ubiquitous regulators of cellular signaling pathways.

Authors:  Eugenia V Gurevich; Vsevolod V Gurevich
Journal:  Genome Biol       Date:  2006       Impact factor: 13.583

9.  Modular mass spectrometric tool for analysis of composition and phosphorylation of protein complexes.

Authors:  Justin D Blethrow; Chao Tang; Changhui Deng; Andrew N Krutchinsky
Journal:  PLoS One       Date:  2007-04-04       Impact factor: 3.240

Review 10.  Location, location, location...site-specific GPCR phosphorylation offers a mechanism for cell-type-specific signalling.

Authors:  Andrew B Tobin; Adrian J Butcher; Kok Choi Kong
Journal:  Trends Pharmacol Sci       Date:  2008-07-06       Impact factor: 14.819

View more
  19 in total

Review 1.  The apelinergic system: a perspective on challenges and opportunities in cardiovascular and metabolic disorders.

Authors:  Eric Marsault; Catherine Llorens-Cortes; Xavier Iturrioz; Hyung J Chun; Olivier Lesur; Gavin Y Oudit; Mannix Auger-Messier
Journal:  Ann N Y Acad Sci       Date:  2019-06-25       Impact factor: 5.691

Review 2.  Biased signalling: from simple switches to allosteric microprocessors.

Authors:  Jeffrey S Smith; Robert J Lefkowitz; Sudarshan Rajagopal
Journal:  Nat Rev Drug Discov       Date:  2018-01-05       Impact factor: 84.694

Review 3.  Advances in therapeutic peptides targeting G protein-coupled receptors.

Authors:  Anthony P Davenport; Conor C G Scully; Chris de Graaf; Alastair J H Brown; Janet J Maguire
Journal:  Nat Rev Drug Discov       Date:  2020-03-19       Impact factor: 84.694

Review 4.  Apelinergic System Structure and Function.

Authors:  Kyungsoo Shin; Calem Kenward; Jan K Rainey
Journal:  Compr Physiol       Date:  2017-12-12       Impact factor: 9.090

5.  C-X-C Motif Chemokine Receptor 3 Splice Variants Differentially Activate Beta-Arrestins to Regulate Downstream Signaling Pathways.

Authors:  Jeffrey S Smith; Priya Alagesan; Nimit K Desai; Thomas F Pack; Jiao-Hui Wu; Asuka Inoue; Neil J Freedman; Sudarshan Rajagopal
Journal:  Mol Pharmacol       Date:  2017-05-30       Impact factor: 4.436

Review 6.  Intrinsically disordered proteins and proteins with intrinsically disordered regions in neurodegenerative diseases.

Authors:  Orkid Coskuner-Weber; Ozan Mirzanli; Vladimir N Uversky
Journal:  Biophys Rev       Date:  2022-06-08

7.  Cardiovascular response to small-molecule APJ activation.

Authors:  Brandon Ason; Yinhong Chen; Qi Guo; Kimberly M Hoagland; Ray W Chui; Mark Fielden; Weston Sutherland; Rhonda Chen; Ying Zhang; Shirley Mihardja; Xiaochuan Ma; Xun Li; Yaping Sun; Dongming Liu; Khanh Nguyen; Jinghong Wang; Ning Li; Sridharan Rajamani; Yusheng Qu; BaoXi Gao; Andrea Boden; Vishnu Chintalgattu; Jim R Turk; Joyce Chan; Liaoyuan A Hu; Paul Dransfield; Jonathan Houze; Jingman Wong; Ji Ma; Vatee Pattaropong; Murielle M Véniant; Hugo M Vargas; Gayathri Swaminath; Aarif Y Khakoo
Journal:  JCI Insight       Date:  2020-04-23

Review 8.  Biased signaling in naturally occurring mutations of G protein-coupled receptors associated with diverse human diseases.

Authors:  Li-Kun Yang; Zhi-Shuai Hou; Ya-Xiong Tao
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2020-09-17       Impact factor: 5.187

Review 9.  Apelin, Elabela/Toddler, and biased agonists as novel therapeutic agents in the cardiovascular system.

Authors:  Peiran Yang; Janet J Maguire; Anthony P Davenport
Journal:  Trends Pharmacol Sci       Date:  2015-07-01       Impact factor: 14.819

Review 10.  International Union of Basic and Clinical Pharmacology. CVII. Structure and Pharmacology of the Apelin Receptor with a Recommendation that Elabela/Toddler Is a Second Endogenous Peptide Ligand.

Authors:  Cai Read; Duuamene Nyimanu; Thomas L Williams; David J Huggins; Petra Sulentic; Robyn G C Macrae; Peiran Yang; Robert C Glen; Janet J Maguire; Anthony P Davenport
Journal:  Pharmacol Rev       Date:  2019-10       Impact factor: 25.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.